NTLA
Price
$16.31
Change
-$0.30 (-1.81%)
Updated
Sep 26 closing price
Capitalization
1.75B
39 days until earnings call
VANI
Price
$1.43
Change
-$0.00 (-0.00%)
Updated
Sep 26 closing price
Capitalization
84.72M
51 days until earnings call
Interact to see
Advertisement

NTLA vs VANI

Header iconNTLA vs VANI Comparison
Open Charts NTLA vs VANIBanner chart's image
Intellia Therapeutics
Price$16.31
Change-$0.30 (-1.81%)
Volume$6.6M
Capitalization1.75B
Vivani Medical
Price$1.43
Change-$0.00 (-0.00%)
Volume$61.64K
Capitalization84.72M
NTLA vs VANI Comparison Chart in %
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VANI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. VANI commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and VANI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (NTLA: $16.31 vs. VANI: $1.43)
Brand notoriety: NTLA and VANI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 122% vs. VANI: 40%
Market capitalization -- NTLA: $1.75B vs. VANI: $84.72M
NTLA [@Biotechnology] is valued at $1.75B. VANI’s [@Biotechnology] market capitalization is $84.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileVANI’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • VANI’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than VANI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 6 TA indicator(s) are bullish while VANI’s TA Score has 6 bullish TA indicator(s).

  • NTLA’s TA Score: 6 bullish, 4 bearish.
  • VANI’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both NTLA and VANI are a good buy in the short-term.

Price Growth

NTLA (@Biotechnology) experienced а +4.62% price change this week, while VANI (@Biotechnology) price change was +1.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

NTLA is expected to report earnings on Nov 06, 2025.

VANI is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.75B) has a higher market cap than VANI($84.7M). NTLA YTD gains are higher at: 39.880 vs. VANI (23.276). VANI has higher annual earnings (EBITDA): -26.38M vs. NTLA (-501.87M). NTLA has more cash in the bank: 460M vs. VANI (6.79M). VANI has less debt than NTLA: VANI (18.6M) vs NTLA (103M). NTLA has higher revenues than VANI: NTLA (52.9M) vs VANI (0).
NTLAVANINTLA / VANI
Capitalization1.75B84.7M2,067%
EBITDA-501.87M-26.38M1,902%
Gain YTD39.88023.276171%
P/E RatioN/AN/A-
Revenue52.9M0-
Total Cash460M6.79M6,771%
Total Debt103M18.6M554%
FUNDAMENTALS RATINGS
NTLA vs VANI: Fundamental Ratings
NTLA
VANI
OUTLOOK RATING
1..100
2697
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3743
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a29

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for VANI (70) in the null industry. This means that NTLA’s stock grew somewhat faster than VANI’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VANI (100) in the null industry. This means that NTLA’s stock grew similarly to VANI’s over the last 12 months.

NTLA's SMR Rating (98) in the Biotechnology industry is in the same range as VANI (100) in the null industry. This means that NTLA’s stock grew similarly to VANI’s over the last 12 months.

NTLA's Price Growth Rating (37) in the Biotechnology industry is in the same range as VANI (43) in the null industry. This means that NTLA’s stock grew similarly to VANI’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as VANI (100) in the null industry. This means that NTLA’s stock grew similarly to VANI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAVANI
RSI
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
75%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
78%
MACD
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 11 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VANI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FSPKF21.79N/A
N/A
Fisher & Paykel Healthcare Corp. Ltd.
CYTOF0.06N/A
N/A
Altamira Therapeutics Ltd.
CLCMF3.03N/A
N/A
Sinch AB
HSTI1.40N/A
N/A
High Sierra Technologies Inc.
SVMLF0.45-0.01
-3.11%
Sovereign Metals Ltd.

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been loosely correlated with BEAM. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if NTLA jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.81%
BEAM - NTLA
63%
Loosely correlated
-0.52%
CRSP - NTLA
62%
Loosely correlated
+2.24%
RXRX - NTLA
54%
Loosely correlated
+1.94%
ABCL - NTLA
50%
Loosely correlated
+1.94%
ALLO - NTLA
50%
Loosely correlated
+4.17%
More

VANI and

Correlation & Price change

A.I.dvisor indicates that over the last year, VANI has been loosely correlated with VTVT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if VANI jumps, then VTVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VANI
1D Price
Change %
VANI100%
N/A
VTVT - VANI
59%
Loosely correlated
-2.10%
ENVB - VANI
41%
Loosely correlated
-0.62%
NTLA - VANI
30%
Poorly correlated
-1.81%
KYTX - VANI
29%
Poorly correlated
-3.94%
GLABF - VANI
29%
Poorly correlated
N/A
More